PPT-Idiopathic pulmonary fibrosis (IPF)

The need for early recognition and referral PRC2128 It can be difficult to separate idiopathic pulmonary fibrosis IPF from other conditions IPF is a rare but fatal lung disease with a lower survival rate than many common malignancies. F Mexico Idiopathic pulmonary fibrosis IPF a progressive and relentless lung scarring of unknown etiology has been recognized as the most lethal interstitial lung disease Despite the growing interest in IPF the precise molecular mechanisms underlying Lung Disease. Nicholas Ashley SHO. Definition – . Interstital. Fibrosis. Chronic inflammatory condition of the lung parenchyma that has multiple . aetiologies. but ultimately results in fibrosis of the alveoli and . ( DIFFUSE PARENCHYMAL LUNG DISEASE ). (Restrictive pulmonary Diseases). INTRODUCTION. . Restrictive lung diseases: . Intrinsic lung diseases. : alteration in lung parenchyma. Extrinsic lung diseases. Abstract ID -1188. 72yrs . male. Chronic smoker. Presented with . complaints of cough with breathlessness . for last 3months . PFT:. Near normal . spirometry and lung volume . Reduced diffusion . capacity . – . The need for early recognition and referral. PRC-2128. It can be difficult to separate idiopathic pulmonary fibrosis (IPF) from other conditions. IPF is a rare but fatal lung disease, with a lower survival rate than many common malignancies. Overview of IPF. Overview of IPF (cont). The Role of HRCT in Assessing IPF. HRCT Techniques. Early HRCT Findings in IPF. Hypersensitivity Pneumonitis. HRCT Features and Distribution in Lungs. Definite UIP (All 4 Features). Diagnosing Idiopathic Pulmonary Fibrosis. FACULTY. Title. Affiliation. Learning Objectives. Explain the considerations associated with . clinical evaluation, imaging, and . biopsy. , in terms of differentially diagnosing . Idiopathic Pulmonary Fibrosis (IPF) Hams et al. iden��ed a poten�al role for IL-17E in the genera�on of pulmonary �brosis via the ac� PULMONARY FIBROSIS MANAGEMENT STRATEGIES I. NOVEMBER 13, 2015. Pharmacologic therapy. Disclosures. Research Grants. Roche (. InterMune. ). Scientific Advisory Board . Roche (. InterMune. ). Boehringer. and Why. SESSION LEADERS: . JOAO ALBERTO M. DE ANDRADE, MD . JOYCE LEE, MD. What is pulmonary fibrosis and. why is it a problem?. JOYCE S. LEE, MD. PULMONARY FIBROSIS: WHAT AND WHY. NOVEMBER 13, 2015. IMRE NOTH, MD. CLINICAL CARE: NEW AND EVOLVING TREATMENT STRATEGIES . NOVEMBER 14, 2015. What is “Precision” Medicine?. Precision medicine. is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.. Bahman Saatian, M.D.. Pulmonary Critical Care Medicine. UC Irvine Medical Center. September 8 2014. OBJECTIVES. Review the spectrum of ILD. Identify the clues on presentation to make the diagnosis. Current Definition of IPF. IPF. Specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. Limited to the lungs. Occurs primarily in older adults. Raghu G, et al. . Am J . for PF x /MCxID 7x8 00x /MCxID 7x8 00The challenge will culminate in a final pitch day the week of November 16 2020 The top solution will receive 50000 and a one-year membership at MATTER x /MCxID 7x